866-997-4948(US-Canada Toll Free)

Lung Adenocarcinoma - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Oncology

No. of Pages : 57 Pages


Global Markets Directs, \'Lung Adenocarcinoma Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lung Adenocarcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma. 

Lung Adenocarcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Lung Adenocarcinoma.
  • A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Lung Adenocarcinoma pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lung Adenocarcinoma Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Lung Adenocarcinoma 7
Lung Adenocarcinoma Therapeutics under Development by Companies 9
Lung Adenocarcinoma Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Lung Adenocarcinoma Therapeutics - Products under Development by Companies 15
Lung Adenocarcinoma Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Lung Adenocarcinoma Therapeutics Development 17
Boehringer Ingelheim GmbH 17
Amgen Inc. 18
AstraZeneca PLC 19
Pfizer Inc. 20
Morphotek, Inc. 21
BioNumerik Pharmaceuticals, Inc. 22
Lung Adenocarcinoma - Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Combination Products 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
dacomitinib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
MT-110 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
dimesna - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
farletuzumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
GM.CD40L cell vaccine + [cyclophosphamide] + [tretinoin] - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BLP25 Liposome Vaccine + [bevacizumab] + [carboplatin] + [cyclophosphamide] + [paclitaxel] + Radiation Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
afatinib - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
dimesna + [cisplatin] + [docetaxel] - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
licofelone - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Lung Adenocarcinoma Therapeutics - Drug Profile Updates 46
Lung Adenocarcinoma - Product Development Milestones 54
Featured News & Press Releases 54
Apr 20, 2012: Endocyte Presents Data On Vintafolide At European Lung Cancer Conference 54

Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Table


Number of Products Under Development for Lung Adenocarcinoma, H1 2013 7
Products under Development for Lung Adenocarcinoma - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Early Clinical Stage Development, H1 2013 13
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 14
Products under Development by Companies, H1 2013 15
Products under Investigation by Universities/Institutes, H1 2013 16
Boehringer Ingelheim GmbH, H1 2013 17
Amgen Inc., H1 2013 18
AstraZeneca PLC, H1 2013 19
Pfizer Inc., H1 2013 20
Morphotek, Inc., H1 2013 21
BioNumerik Pharmaceuticals, Inc., H1 2013 22
Assessment by Monotherapy Products, H1 2013 23
Assessment by Combination Products, H1 2013 24
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Stage and Molecule Type, H1 2013 28
Lung Adenocarcinoma Therapeutics - Drug Profile Updates 46

List of Chart


Number of Products under Development for Lung Adenocarcinoma, H1 2013 7
Products under Development for Lung Adenocarcinoma - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Early Clinical Stage Products, H1 2013 13
Pre-Clinical Stage Products, H1 2013 14
Assessment by Monotherapy Products, H1 2013 23
Assessment by Combination Products, H1 2013 24
Assessment by Route of Administration, H1 2013 25
Assessment by Stage and Route of Administration, H1 2013 26
Assessment by Molecule Type, H1 2013 27
Assessment by Stage and Molecule Type, H1 2013 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *